Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Operating expenses:
Research and development	$ 39,528	$ 11,057	$ 94,025	$ 19,633
General and administrative	11,153	3,984	29,518	5,002
Total operating expenses	50,681	15,041	123,543	24,635
Loss from operations	(50,681)	(15,041)	(123,543)	(24,635)
Other income (expense):
Change in fair value of preferred stock tranche liability				(17,030)
Interest income	37		143
Interest expense	(543)	(1)	(737)	(28)
Total other expense, net	(506)	(1)	(594)	(17,058)
Net loss	$ (51,187)	$ (15,042)	$ (124,137)	$ (41,693)
Net loss per common share, basic and diluted	$ (1.35)	$ (1.28)	$ (3.31)	$ (3.73)
Weighted average common shares outstanding, basic and diluted	38,003,954	11,733,170	37,495,537	11,176,429